ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune checkpoint inhibitors targeting CTLA4 and PD-1/PD-L1 show promise but have moderate clinical success rates.
• Novel checkpoint molecules and tolerogenic pathways are needed to improve tumor immunotherapy.
• Immunoglobulin-like transcript 4 (ILT4) is an immunosuppressive molecule expressed in myeloid cells and enriched in various cancer types.

Purpose of the Study:

• To explore the functional role of ILT4 as a novel immune checkpoint in cancer.
• To discuss ILT4-mediated mechanisms in tumor development, immune escape, and the tumor microenvironment.
• To highlight ILT4 as a potential therapeutic target for cancer immunotherapy.

Main Methods:

• Literature review of studies on ILT4 expression and function in cancer.
• Analysis of ILT4's role in modulating tumor cell behavior and immune responses.
• Discussion of ILT4's contribution to the tumor suppressive microenvironment.

Main Results:

• ILT4 is enriched in tumor cells and stroma, promoting tumor immune escape.
• ILT4 impairs effector anti-tumor immune responses.
• ILT4 sustains a tumor-supportive microenvironment.

Conclusions:

• ILT4 plays a significant role in cancer progression and immune evasion.
• Targeting ILT4 represents a promising novel strategy for cancer immunotherapy.
• Further understanding of ILT4 is crucial for developing new cancer treatments.